Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Gadolinium Deposition Disease Explained: How It Is Diagnosed, And More

May 16, 2018 By Law Offices of Thomas J. Lamb, P.A.

A person who received an injection of a gadolinium-based contrast agent (GBCA) may develop some medical conditions following their MRI or MRA procedure which could be symptoms of gadolinium deposition disease.

These various gadolinium-related symptoms include:

  • Persistent headache;
  • “Brain fog”;
  • Skin that appears spongy or rubbery, which is actually subcutaneous soft tissue thickening;
  • Tendons and ligaments which are painful and have a thickened appearance;
  • Bone and joint pain;
  • Tightness in hands and feet; and,
  • Pain described as burning, cutting, or “pins and needles” in the arms or legs and the torso.

If a person starts experiencing one or more of these symptoms within two months after a gadolinium contrast agent was used, they may have developed gadolinium deposition disease (gadolinium toxicity or poisoning) due to the GBCA injection they received for their MRI.

Where gadolinium deposition disease is suspected by a patient or a doctor, testing for retained gadolinium is the next step in determining whether the symptoms are, in fact, due to the gadolinium contrast agent used for the MRI or MRA. There are two types of tests which might be used:

  1. 24-hour urine gadolinium test; and
  2. Heavy metal testing using blood, hair or nail samples, or urine.

If one or both of these tests are “positive” for gadolinium, the symptoms experienced by that person may be diagnosed by a doctor as gadolinium deposition disease.

Our law firm is investigating possible products liability lawsuits against the pharmaceutical companies responsible for the gadolinium-based contrast agents, or contrast dyes, which might cause any of the several symptoms that fall under the gadolinium deposition disease diagnosis label.

[View article at original source]

Gadolinium-Containing Contrast Agents

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: gadolinium, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents, gadolinium-containing contrast

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.